Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Rises By 170.1%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 372,500 shares, a growth of 170.1% from the February 28th total of 137,900 shares. Based on an average daily volume of 128,900 shares, the days-to-cover ratio is currently 2.9 days. Currently, 5.0% of the company’s stock are short sold.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MRKR. NEA Management Company LLC increased its position in shares of Marker Therapeutics by 51.7% in the 4th quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock valued at $5,056,000 after purchasing an additional 554,250 shares during the last quarter. Millennium Management LLC purchased a new position in Marker Therapeutics in the fourth quarter valued at $50,000. Alyeska Investment Group L.P. acquired a new stake in Marker Therapeutics in the fourth quarter valued at $2,847,000. Northern Trust Corp lifted its holdings in Marker Therapeutics by 66.9% during the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after buying an additional 21,703 shares during the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in Marker Therapeutics during the 4th quarter worth about $1,724,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MRKR. Canaccord Genuity Group started coverage on shares of Marker Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $8.00 price objective for the company. Brookline Capital Management raised shares of Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th.

Marker Therapeutics Price Performance

MRKR stock traded down $0.10 during mid-day trading on Friday, reaching $1.27. The company had a trading volume of 38,420 shares, compared to its average volume of 58,693. The firm has a fifty day simple moving average of $1.63 and a 200 day simple moving average of $2.73. Marker Therapeutics has a fifty-two week low of $1.13 and a fifty-two week high of $5.99.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.